| Metric | Q2'26 | Q3'26 | Change |
|---|---|---|---|
| Revenue | $2.89B, +19% YoY | ~$3.0B, +22% YoY | Accelerating despite procedure deceleration |
| Non-GAAP EPS | $2.80, +28% YoY | $3.00, +25% YoY | Growth rate decelerating 300bps |
| GAAP Net Income | $818M / $2.29 EPS | $523M / $1.49 EPS | Down 25.7% YoY versus $704M; approximately 36% decline is sequential versus $818M |
| Non-GAAP Operating Margin | 42% | 42% (41% ex-tariff refund) | Flat |
| US da Vinci procedure growth | 12% | 10% | Down 2 percentage points versus Q2 growth rate; no historical superlative established |
| Total procedure growth (DV+ION) | 16% | 15% | Mild deceleration |
| ION procedure growth | 36% | 31% | -500bps deceleration |
| SP procedure growth | 61% | 55% | -600bps deceleration |
| da Vinci INA revenue per procedure | ~$1,830 | ~$1,860 | Up modestly ahead of 3-5% pricing cuts landing in 2027 |
| US ASC installs | 27 systems | 18 systems | Down 9 systems sequentially; a pipeline can grow while quarterly placements fall |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.